S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD
About this episode
Dr. Kruse discusses the impact of FES-PET/CT on treatment planning for lobular breast cancer.
Dr Kruse discussed the evolving role of FES-PET/CT in breast cancer, particularly invasive lobular carcinoma. She explained that FES-PET/CT uses a radiotracer to map estrogen receptor–positive cancer sites, offering advantages over traditional imaging. FIndings from a study presented at the 2025 San Antonio Breast Cancer Symposium showed that many patients experienced treatment changes based on FES-PET/CT results. The National Comprehensive Cancer Network guidelines also now recommend FES-PET/CT for use in lobular breast cancer, enhancing its clinical utility. Dr Kruse concluded by emphasizing that future research is needed to explore its use in early-stage breast cancer and for monitoring endocrine therapy response.
More episodes of OncLive® On Air
- S17 Ep18: Metastatic Bladder Cancer 2026 UPDATE
- S17 Ep14: Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD
- S17 Ep13: Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer
- S17 Ep12: ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD
- S17 Ep11: Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas
- S17 Ep10: Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD
Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.